Payment overview · 2025
General Payments
$248.53
13 reported records · 8 companies
Healthcare provider profile · identity verified
Michael Paul Kane, MD
Allopathic & Osteopathic Physicians|Family Medicine · HAMBURG, NY · NPI 1790728004
Verified facts
What the public records show
CMS Open Payments records show Michael Paul Kane, MD received $248.53 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 28.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $70.25 | 28.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.36 | 17.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.69 | 12.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.39 | 11.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.05 | 8.9% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.80 | 8.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.22 | 6.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.77 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $248.53 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $70.25 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.39 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.54 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
131 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 357 | 110 |
| Atorvastatin Calcium | Atorvastatin Calcium | 347 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 312 | 91 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 273 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 266 | 74 |
| Metformin Hcl | Metformin Hcl | 213 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 200 | 56 |
| Omeprazole | Omeprazole | 181 | 57 |
| Simvastatin | Simvastatin | 145 | 40 |
| Gabapentin | Gabapentin | 144 | 40 |
| Alprazolam | Alprazolam | 138 | 47 |
| Eliquis | Apixaban | 131 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 37 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 121 | 35 |
| Famotidine | Famotidine | 118 | 34 |
| Losartan Potassium | Losartan Potassium | 111 | 28 |
| Meloxicam | Meloxicam | 109 | 35 |
| Furosemide | Furosemide | 108 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 103 | 33 |
| Allopurinol | Allopurinol | 97 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 92 | 25 |
| Trazodone Hcl | Trazodone Hcl | 88 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 82 | 27 |
| Warfarin Sodium | Warfarin Sodium | 75 | 19 |
| Irbesartan | Irbesartan | 74 | 21 |
| Ibuprofen | Ibuprofen | 72 | 26 |
| Buspirone Hcl | Buspirone Hcl | 71 | 16 |
| Diazepam | Diazepam | 71 | 16 |
| Potassium Chloride | Potassium Chloride | 67 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 14 |
| Sertraline Hcl | Sertraline Hcl | 64 | 18 |
| Tramadol Hcl | Tramadol Hcl | 64 | 26 |
| Jardiance | Empagliflozin | 59 | 13 |
| Bupropion Xl | Bupropion Hcl | 57 | 16 |
| Celecoxib | Celecoxib | 56 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 17 |
| Ozempic | Semaglutide | 51 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 49 | 17 |
| Xarelto | Rivaroxaban | 48 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Glipizide | Glipizide | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Enalapril Maleate | Enalapril Maleate | 41 | 13 |
| Prednisone | Prednisone | 38 | 32 |
| Azelastine Hcl | Azelastine Hcl | 36 | 14 |
| Meclizine Hcl | Meclizine Hcl | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Ramipril | Ramipril | 35 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 24 |
| Valsartan | Valsartan | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 25 |
| Bumetanide | Bumetanide | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Nystatin | Nystatin | 25 | 17 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 23 |
| Clotrimazole | Clotrimazole | 23 | 12 |
| Methylprednisolone | Methylprednisolone | 23 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | 12 |
| Folic Acid | Folic Acid | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Indapamide | Indapamide | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 11 |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Phenazopyridine Hcl | Phenazopyridine Hcl | 11 | suppressed |
| Striverdi Respimat | Olodaterol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $248.53 · 13 records | Exact Sciences Corporation | AIRSUPRA, Auvelity, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ENFLONSIA, EVENITY, GARDASIL 9, OTEZLA, Omnipod, Ozempic, PENBRAYA, PREVNAR 20, PROLIA, REPATHA, Rybelsus | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error